Search

VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for once-daily administration In the VIRGO trial evaluating twice-daily [...]

- The 24-week integrated results from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluated the efficacy and safety of risankizumab (SKYRIZI) versus placebo for the treatment of [...]

- In Crohn's disease patients with clinical response to risankizumab IV induction treatment, a significantly greater proportion of patients treated with risankizumab 360 mg SC achieved endoscopic response and clinical [...]

NORTH CHICAGO, Ill., May 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials -- Measure Up [...]

- In SELECT-PsA 1, RINVOQ(TM) (upadacitinib, 15 mg and 30 mg) improved key joint and skin symptoms up to 24 weeks, including enthesitis[1] - Both doses of upadacitinib significantly improved [...]

- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving [...]

- Presbyopia is a common, progressive condition that reduces the aging eye's ability to focus on near objects and affects nearly four out of 10 people in the U.S. - [...]

- Data from Phase 3 VIALE-A study showed venetoclax plus azacitidine reduced the risk of death by 34% compared to azacitidine plus placebo in newly-diagnosed patients with AML who are [...]

DUBLIN: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

DUBLIN: Research and Markets has issued the following news release: The 'Alzheimer's Disease Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Summary The clinical [...]

DUBLIN: Research and Markets has issued the following news release: The 'Wrinkles Global Clinical Trials Review, H2, 2019' clinical trials has been added to ResearchAndMarkets.com's offering. Wrinkles Global Clinical Trials [...]

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the [...]

-- Published data from a second robust Phase 3 clinical trial demonstrated efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist (gepant) -- -- Compared to placebo, ubrogepant [...]

DUBLIN: Allergan plc has issued the following press release: Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the [...]

-- Pivotal Phase 3 clinical trial reinforced efficacy, safety and tolerability of ubrogepant, an orally-administered CGRP receptor antagonist (gepant) -- -- Acute treatment of migraine with ubrogepant compared with placebo [...]

DUBLIN: Allergan plc has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (SIX: [...]

- Two-year results from CEDAR and SEQUOIA demonstrate that vision gains observed after one year with every 8-week and every 12-week dosing were maintained in the second year - - [...]

Massachusetts: Editas Medicine, Inc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, [...]

SAN FRANCISCO and DUBLIN: Medicines360 has issued the following news release: Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc [...]

Six-Year, Multi-Center, Pivotal Clinical Trial Data of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg Presented at 2019 ACOG Meeting SAN FRANCISCO and DUBLIN, May 6, 2019 /PRNewswire/ -- Medicines360, a nonprofit [...]

Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan [...]

DUBLIN: Allergan plc has issued the following news release:Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced positive 3-month topline results from the second pivotal clinical trial of [...]

- These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year - - Allergan plans US NDA submission in [...]

Reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care EDIT-101 is Editas Medicine's experimental CRISPR genome editing medicine for the treatment of [...]

Zurich, Switzerland: SIX Swiss Exchange Ltd has issued the following notice: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing [...]

Abicipar, the first and only anti-VEGF to maintain stable vision in greater than 91 percent of patients on a fixed 12-week regimen, achieved the primary endpoint of non-inferiority to monthly [...]

DUBLIN: Allergan plc has issued the following press release: - Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced the release of new topline clinical trial data on [...]

- Study meets primary endpoint for all doses and dose regimens - - Atogepant was well tolerated and there was no signal of hepatotoxicity with daily administration over 12 weeks [...]

SAN FRANCISCO: Medicines360 has issued the following news release: Medicines360, a nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), [...]

Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting SAN FRANCISCO and DUBLIN, April 30, 2018 /PRNewswire/ -- [...]

Dublin: Allergan plc (AGN) has issued the following press release: Allergan plc, (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE II (UBR-MD-02), the second of [...]

Primary endpoint was met in the study evaluating patients with acute bipolar I depression treated with cariprazine 1.5 mg versus placebo Efficacy and safety of cariprazine in adults with bipolar [...]

Dublin: Allergan plc (AGN) has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first [...]

Republic of Ireland: Allergan has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first [...]

California: Allergan, Plc has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of [...]

Oakland: Allergan has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the first of two [...]

Allergan plc. : Allergan plc. has issued the following press release: Allergan plc , (NYSE: AGN), a leading global pharmaceutical company today announced positive results from ACHIEVE I (UBR-MD-01), the [...]

- Topline results from ACHIEVE I (UBR-MD-01) study demonstrate efficacy, safety and tolerability - - Study meets Co-Primary Endpoints in First of Two Phase 3 Studies - DUBLIN, Feb. 6, [...]

Coolock: Allergan Pharmaceutical company has issued the following news release: DUBLIN and BUDAPEST, Hungary, Dec. 18, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Gedeon [...]

-- Additional data from the Phase 3 VENUS II trial evaluated absence of bleeding in two courses of treatment -- -- Sub-analysis from VENUS II assessed impact on quality of [...]

- Application Seeks to Expand Label to Include an Indication and Phase 3 Data for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia (HABP/VABP) - DUBLIN, Oct. 2, [...]

-- Liver Biopsy Data from New One Year Cohort of Patients Receiving CVC Confirm the Anti-Fibrotic Activity of CVC in Patients with Fibrosis of NASH -- -- In Patients Treated [...]

Calif: Allergan plc has issued the following news release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced topline data from a Phase II study with Major Depressive [...]

Allergan plc.: Allergan plc. has issued the following press release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced topline data from a Phase II study with Major [...]

Calif: Allergan plc has issued the following news release: Allergan announced to advance its wrinkle treatment Botox to third phase after its phase II study showed a partial benefit in [...]

Calif: Allergan plc has issued the following news release: Allergan and Paratek Pharmaceuticals' acne drug sarecycline has met its primary efficacy endpoints in two phase 3 trials. The studies have [...]

Program on Track for FDA Submission in the Second Half of 2017 DUBLIN and BOSTON, March 27, 2017 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and [...]